EMERGEN 2.0

Emergent BioSolutions is a global life sciences company focused on providing specialized products for public health threats, including medical countermeasures for biological and chemical agents and opioid overdose. The company is widely recognized for its over-the-counter naloxone product, Narcan, and its portfolio of vaccines and therapeutics for anthrax and smallpox. Recently, the company has undergone a strategic transformation, often referred to as "Emergent 2.0," to streamline operations, reduce debt, and focus on its core commercial and government-contracted products. Emergent also operates as a contract development and manufacturing organization (CDMO), supporting the production of vaccines and biologics for various partners.